|
| Press Releases |
|
 |
|
| Friday, June 23, 2017 |
|
|
Eisai Submits Application for Additional Indication of Anticancer Agent Lenvima for Hepatocellular Carcinoma in Japan |
| Eisai Co., Ltd. announced today that it has submitted an application for an additional indication of its in-house discovered and developed anticancer agent Lenvima (generic name: lenvatinib mesylate) for the treatment of hepatocellular carcinoma (HCC) in Japan, the first in the world. more info >> |
|
|
Cardiovascular Outcomes Trial of Anti-Obesity Agent Lorcaserin to Continue Based on Recommendation of Independent Data Monitoring Committee After Completion of Interim Safety Analysis |
| Eisai Co., Ltd. has announced that it has received a recommendation from an independent Data Monitoring Committee to continue the ongoing Cardiovascular Outcomes Trial of lorcaserin hydrochloride after the completion of a pre-specified interim safety analysis, evaluating the incidence of Major Adverse Cardiovascular Events (MACE), defined as cardiovascular death, myocardial infarction or stroke. more info >> |
|
| Thursday, June 8, 2017 |
|
|
Launch of Pain Treatment Lyrica OD Tablet Formulation in Japan |
| Pfizer Japan Inc. and Eisai Co., Ltd. have announced that Lyrica OD Tablets 25mg, 75mg, 150mg (OD tablet: orally disintegrating tablet), a new formulation following pain treatment Lyrica Capsules (pregabalin). more info >> |
|
| Monday, June 5, 2017 |
|
|
Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-Line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that the results of a Phase III trial (Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylate against the comparator sorafenib as first-line treatment for unresectable hepatocellular carcinoma, will be orally presented during the 53rd Annual Meeting of ASCO. more info >> |
|
|
Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab |
| Eisai Co., Ltd. announced the first results for metastatic endometrial carcinoma obtained from a Phase Ib/II study (Study 111) of its in-house developed multi-kinase inhibitor lenvatinib mesylate in combination with the MSD anti-PD-1 antibody pembrolizumab (brand name: KEYTRUDA), during a presentation at the 53rd Annual Meeting of ASCO. more info >> |
|
| Thursday, June 1, 2017 |
|
|
Eisai Commits Funding to the 2nd Phase of Global Health Innovative Technology Fund Activities |
| Eisai Co., Ltd. has announced that it will grant a total of 500 million yen to the Global Health Innovative Technology Fund (GHIT Fund) to fund the second phase of its activities, which will take place in the five-year period from FY 2018 to FY 2022. more info >> |
|
| Wednesday, May 31, 2017 |
|
|
Eisai Enters Into a New Joint Research Agreement With the Broad Institute to Develop an Antimalarial Medicine |
| Eisai Co., Ltd. announced today that it has entered into a new joint research agreement with the Broad Institute, a collaborative research institute which includes researchers from the Massachusetts Institute of Technology and Harvard University to develop a new antimalarial medicine based on antimalarial drug targets the team identified last year. more info >> |
|
| Thursday, May 18, 2017 |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at 53rd ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results for its in-house discovered lenvatinib mesylate and eribulin mesylate, as well as H3B-8800 will be presented during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO). more info >> |
|
| Wednesday, April 19, 2017 |
|
|
Eisai Announces Results and Continued Support of Initiatives for Elimination of Lymphatic Filariasis |
| Eisai Co., Ltd. has announced the results of its initiatives for the elimination of lymphatic filariasis (LF), and its continued support of this cause in the future. more info >> |
|
| Tuesday, April 11, 2017 |
|
|
Eisai to Launch "Chocola BB Gold Rich" Highest Combination of Active Ingredients in Chocola BB Series |
| Eisai Co., Ltd. announced today that, approaching the 65th anniversary of its Chocola BB brand, it will launch Chocola BB Gold Rich (designated quasi-drug), a supplement drink recommended to relieve fatigue, on Monday, April 17. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
BW Digital and BW ESS launch BW Velora to drive greater digital sustainability 
Jun 23, 2025 00:17 HKT/SGT
|
|
|
New method to blend functions for soft electronics
Jun 23, 2025 00:15 HKT/SGT
|
|
|
Ditchit Detonates Iconic Twitter Bird to Symbolize Launch of Local Marketplace
Jun 21, 2025 06:00 HKT/SGT
|
|
|
Shaping a New Platform for Global Growth Discussed at Open Dialogue within SPIEF-2025
Jun 20, 2025 23:00 HKT/SGT
|
|
|
Global Economic Shifts in Focus as Madrid Professor Addresses SPIEF 2025 Opening Session
Jun 20, 2025 23:00 HKT/SGT
|
|
|
QS Energy Receives Initial Order for Multi-Year AOT Technology Deployment
Jun 20, 2025 21:00 HKT/SGT
|
|
|
CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health
Jun 20, 2025 19:06 JST
|
|
|
Legacy and Lifestyle: U.S. Polo Assn. Hosts Iconic Party at Pitti Uomo 108 in Florence, Italy
Jun 19, 2025 22:30 HKT/SGT
|
|
|
Sharp Launches A2 Size ePoster Color Electronic Paper Display
Jun 19, 2025 12:08 JST
|
|
|
CleverTap Launches 'Promos' - The Industry-First All-In-One Rewards Management Platform
Jun 19, 2025 10:19 HKT/SGT
|
|
|
Fujitsu unveils AI-powered presentation technology, enabling automated multilingual and customizable presentations
Jun 19, 2025 10:25 JST
|
|
|
Canstar Strengthens Technical Advisory Board with the Appointment of Geologist and VMS Mineralization Expert, Dr. Stephen J. Piercey, P.Geo., FGC
Jun 19, 2025 09:15 HKT/SGT
|
|
|
ULVAC Continues Participation in "Lab-in-Fab" Project to Advance Piezoelectric MEMS Technology, Now Entering a New Phase
Jun 19, 2025 9:30 JST
|
|
|
Euro Manganese and Integrals Power Sign LOI and Offtake Term Sheet to Strengthen LMFP Battery Supply Chain
Jun 19, 2025 06:59 HKT/SGT
|
|
|
Data Turing Launches to Automate Brand Reputation Using Verifiable Truth
Jun 18, 2025 22:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
